CN Patent

CN102666536A — 新的萘啶衍生物及其作为激酶抑制剂的用途

Assigned to Aeterna Zentaris GmbH · Expires 2012-09-12 · 14y expired

What this patent protects

本发明涉及萘啶类激酶调节剂、它们的制备和作为药物的用途，所述药物用于调节错误方向的细胞信号转导过程，尤其是用于影响酪氨酸和丝氨酸-苏氨酸激酶的功能和用于治疗恶性或良性肿瘤、以及其它基于病理性细胞增殖的疾病，例如，再狭窄、银屑病、动脉硬化和肝硬化。

USPTO Abstract

本发明涉及萘啶类激酶调节剂、它们的制备和作为药物的用途，所述药物用于调节错误方向的细胞信号转导过程，尤其是用于影响酪氨酸和丝氨酸-苏氨酸激酶的功能和用于治疗恶性或良性肿瘤、以及其它基于病理性细胞增殖的疾病，例如，再狭窄、银屑病、动脉硬化和肝硬化。

Drugs covered by this patent

Patent Metadata

Patent number
CN102666536A
Jurisdiction
CN
Classification
—
Expires
2012-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Aeterna Zentaris GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.